A detailed history of Brendel Financial Advisors LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Brendel Financial Advisors LLC holds 4,809 shares of BMY stock, worth $283,105. This represents 0.14% of its overall portfolio holdings.

Number of Shares
4,809
Previous 4,922 2.3%
Holding current value
$283,105
Previous $204,000 22.06%
% of portfolio
0.14%
Previous 0.13%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

SELL
$39.66 - $51.75 $4,481 - $5,847
-113 Reduced 2.3%
4,809 $249,000
Q2 2024

Jul 15, 2024

BUY
$40.25 - $52.99 $198,110 - $260,816
4,922 New
4,922 $204,000
Q4 2023

Feb 01, 2024

BUY
$48.48 - $57.85 $238,618 - $284,737
4,922 New
4,922 $253,000
Q1 2023

Apr 06, 2023

BUY
$65.71 - $74.53 $326,972 - $370,861
4,976 New
4,976 $345,000
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $266,862 - $311,099
4,976 New
4,976 $310,000
Q3 2021

Oct 26, 2021

SELL
$59.17 - $69.31 $294,429 - $344,886
-4,976 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $866 - $981
-15 Reduced 0.3%
4,976 $309,000
Q3 2020

Nov 04, 2020

SELL
$57.43 - $63.64 $7,408 - $8,209
-129 Reduced 2.52%
4,991 $301,000
Q2 2020

Jul 30, 2020

SELL
$54.82 - $64.09 $4,769 - $5,575
-87 Reduced 1.67%
5,120 $301,000
Q2 2019

Aug 15, 2019

BUY
$44.62 - $49.34 $18,874 - $20,870
423 Added 8.84%
5,207 $236,000
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $2,752 - $3,281
-61 Reduced 1.26%
4,784 $228,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $236,242 - $306,349
4,845 New
4,845 $252,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Brendel Financial Advisors LLC Portfolio

Follow Brendel Financial Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brendel Financial Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brendel Financial Advisors LLC with notifications on news.